Article
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2020
Burchert Andreas, Bug Gesine, Fritz Lea V, Finke Jürgen, Stelljes Matthias, Röllig Christoph, Wollmer Ellen, Wäsch Ralph, Bornhäuser Martin, Berg Tobias, Lang Fabian, Ehninger Gerhard, Serve Hubert, Zeiser Robert, Wagner Eva-Maria, Kröger Nicolaus, Wolschke Christine, Schleuning Michael, Götze Katharina S, Schmid Christoph, Crysandt Martina, Eßeling Eva, Wolf Dominik, Wang Ying, Böhm Alexandra, Thiede Christian, Haferlach Torsten, Michel Christian, Bethge Wolfgang, Wündisch Thomas, Brandts Christian, Harnisch Susanne, Wittenberg Michael, Hoeffkes Heinz-Gert, Rospleszcz Susanne, Burchardt Alexander, Neubauer Andreas, Brugger Markus, Strauch Konstantin, Schade-Brittinger Carmen, Metzelder Stephan K
Abstract excerpt
PURPOSE: Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.